Current therapies for chronic hepatitis B virus infection

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 5, 2004, Pages 745-760

  Karayiannis, Peter ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adefovir depivoxil; Antivirals; Hepatitis B virus; Interferon; Lamivudine; Nucleoside analog; Nucleotide analog; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANOREXIA; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; BLEEDING; CHRONIC HEPATITIS; CLINICAL TRIAL; COST OF ILLNESS; DELTA AGENT HEPATITIS; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PATIENT CARE; REVIEW; VARICOSIS;

EID: 5644301428     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.5.745     Document Type: Review

References (142)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 337(24), 1733-1745 (1997).
2. McQuillan GM, Coleman PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am. J. Public Health 89(1), 14-18 (1999).
3. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 60(2), 145-150 (2003).
4. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64(1), 51-68 (2000).
5. Nassal M, Schaller H. Hepatitis B virus replication - an update. J. Viral Hepat. 3(5), 217-226 (1996).
6. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in Hepatitis B viruses. J. Gen. Virol. 83(6), 1267-1280 (2002).
7. Karayiannis P, Carman WF, Thomas HC. Molecular variation in the core promoter, precore and core regions of hepatitis B virus, and their clinical significance. In: Viral Hepatitis, Third Edition. Zuckerman AJ, Thomas HC, Lemon S (Eds). Blackwell, London, UK (2004) (In Press).
8. Chu CM, Karayiannis P, Fowler MJ et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 5(3), 431-434 (1985).
9. Hadziyannis SJ, Vassilopoulos D. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antivir. Res. 52(2), 91-98 (2001).
10. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antingen-negative chronic hepatitis B. Hepatology 34(4 Pt 1), 617-624 (2001).
11. Rizzetto M, Volpes R, Smedile A. Response of precore mutant chronic hepatitis B infection to lamivudine. J. Med. Virol. 61(3), 398-402 (2000).
12. Tang B, Kruger WD, Chen G et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J. Med. Virol. 72(1), 35-40 (2004).
13. Wong DK, Cheung AM, O'Rourke K et al. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 119(4), 312-323 (1993).
14. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? Hepatology 10(5), 761-763 (1989).
15. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34(5), 1021-1026 (2001).
16. Kao JH, Wu NH, Chen PJ et al. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 33(6), 998-1002 (2000).
17. Wai CT, Chu CJ, Hussain M et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36(6), 1425-1430 (2002).
18. Lau DT, Everhart J, Kleiner DE et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon-α. Gastroenterology 113(5), 1660-1667 (1997).
19. Krogsgaard K. The long-term effect of treatment with interferon-α2a in chronic hepatitis B. The Long-term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Antiviral Treatment. J. Viral Hepat. 5(6), 389-397 (1998).
20. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 34(6), 1225-1241 (2001).
21. Manesis EK, Hadziyannis SJ. Interferon-α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121(1), 101-109 (2001).
22. Carreno V, Marcellin P, Hadziyannis S et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon-α2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30(1), 277-282 (1999).
23. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe-positive chronic hepatitis B in α-interferon treated and untreated patients: a long-term cohort study. J. Hepatol. 36(2), 263-270 (2002).
24. Papatheodoridis GV, Manesis E, Hadziyannis S. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 34(2), 306-313 (2001).
25. Erhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31(3), 716-725 (2000).
26. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000, summary of a workshop. Gastroenterology 120(7), 1828-1853 (2001).
27. Lampertico P, Del Ninno E, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37(4), 756-763 (2003).
28. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256-1263 (1999).
29. Lai CL, Chien RN, Leung NW et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis lamivudine Study Group. N. Engl. J. Med. 339(2), 61-68 (1998).
30. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and α-interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46(4), 562-568 (2000).
31. Liaw YF, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119(1), 172-180 (2000).
32. Leung NWY, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33(6), 1527-1532 (2001).
33. Chang TT, Lai CL, Liaw YF et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for 4 years. Antiviral Ther. 5(Suppl. 1), 44 (2000).
34. Chien RN, Liaw YF, Arkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis lamivudine Trial Group. Hepatology 30(3), 770-774 (1999).
35. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36(1), 186-194 (2002).
36. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32(4), 803-806 (2000).
37. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37(4), 748-755 (2003).
38. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 30(4), 1082-1087 (1999).
39. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J. Hepatol. 39(4), 614-619 (2003).
40. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52(3), 420-424 (2003).
41. Jonas MM, Kelley DA, Mizerski J et al., International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 346(15), 1706-1713 (2002).
42. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29(3), 889-896 (1999).
43. Lok ASF, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32(5), 1145-1153 (2000).
44. Santantonio T, Mazzola M, Iacovazzi T et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32(2), 300-306 (2000).
45. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32(4), 847-851 (2000).
46. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32(4), 828-834 (2000).
47. Rizzetto M, Volpes R, Smedile A. Response of precore mutant chronic hepatitis B infection to lamivudine. J. Med. Virol. 61(3), 398-400 (2000).
48. Papatheodoridis GV, Dimou E, Laras A et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36(1), 219-226 (2002 ).
49. Scotto G, Fazio V, Campanozzi F et al. Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: a nonrandomized, open label study. Curr. Ther. Res. 61(6), 321-330 (2000).
50. Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after 1 year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol. 30(5), 743-748. (1999).
51. Tsubota A, Arase Y, Saitoh S et al. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am. J. Gastroenterol. 96(2), 557-562 (2001).
52. Buti M, Cortina M, Jardi R et al. 2 years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J. Viral Hepat. 8(4), 270-275 (2001).
53. Kuwahara R, Kumashiro R, Murashima S et al. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J. Med. Virol. 72(1), 26-34 (2004).
54. Suzuki F, Suzuki Y, Tsubota A et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J. Hepatol. 37(6), 824-830 (2002).
55. Suzuki F. Influence of the hepatitis B e antigen/anti-HBe status on the response to lamivudine. Intervirology 46(6), 339-343 (2003).
56. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 32(5), 1163-1169 (2000).
57. Asahina Y, Izumi N, Uchichara M et al. Core promoter/precore mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J. Hepatol. 39(6), 1063-1069 (2003).
58. Liaw YF, Chien RN, Yeh C et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30(2), 567-572 (1999).
59. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349(9044), 20-22 (1997).
60. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6), 1714-1722 (2003).
61. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27(6), 1670-1677 (1998).
62. Honkoop P, Niesters HG, de Man RA et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26(6), 1393-1395 (1997).
63. Tipples GA, Ma MM, Fischer KP et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24(3), 714-717 (1996).
64. Niesters HG, Honkoop P, Haagsma EB et al. Identification of more than one mutation in the hepatitis B virus polymerase arising during prolonged lamivudine treatment. J. Infect. Dis. 177(5), 1382-1385 (1998).
65. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 51(4 , 761-785 (2003).
66. Calio R, Villani N, Balestra E et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res. 23(1), 77-89 (1994).
67. Westland C, Delaney W 4th, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in Phase III studies of adefovir dipivoxil. Gastroenterology 125(1), 107-116 (2003).
68. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808-816 (2003).
69. Marcellin P, Hadziyannis S, Tassopoulos N et al. 48 weeks of adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and virological status regardless of beseline Knodell fibrosis score in patients with HBeAg-chronic hepatitis B. Hepatology 38(Suppl. 1), 713A (2003).
70. Chang TT, Shiffman M, Tong M et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B. J. Hepatol. 40(Suppl. 1), 126 (2004).
71. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358(9283), 718-723 (2001).
72. Yang H, Westkand CE, Delaney WE et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36(2), 464-473 (2002).
73. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125(2), 292-297 (2003).
74. Hadziyannis S, Tassopoulos N, Chang TT et al. 3 years of study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutants chronic hepatitis B patients in a long-term safety and efficacy study. J. Hepatol. 40(Suppl. 1), 17 (2004).
75. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800-807 (2003). Erratum in: N. Engl. J. Med. 348(12), 1192 (2003).
76. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27(2), 628-633 (1998).
77. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107(4), 449-455 (2001).
78. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 27(6), 1711-1716 (1998).
79. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36(6), 687-696 (2003).
80. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124(1), 105-117 (2003).
81. Liaw YF, Sung JJY, Chow WC et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 38(Suppl. 1), 262A (2003).
82. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126(1), 91-101 (2004).
83. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126(1), 81-90 (2004).
84. de Jongh FE, Janssen HL, de Man RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103(5), 1630-1635 (1992).
85. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21(1), 77-82 (1995).
86. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon-α in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109(3 , 908-916 (1995).
87. Nevens F, Gouba, P, Van Eyken P et al. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon-α. Liver 13(1), 15-19 (1993).
88. Tchervenkov JI, Tector AJ, Barkun JS et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-α pretransplant and hepatitis B immune globulin posttransplant. Ann. Surg. 226(3), 356-365 (1997).
89. Marcellin P, Samuel D, Areias J et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end stage liver disease. Hepatology 19(1), 6-12 (1994).
90. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33(2), 424-432 (2001).
91. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31(1), 207-210 (2000).
92. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol. 33(2), 301-307 (2000).
93. Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 33(2), 308-312 (2000).
94. Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62(10), 1456-1462 (1996).
95. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348(9036), 1212-1215 (1996).
96. Herrero JI, Quiroga J, Sangro B et al. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig. Dis. Sci. 43(6), 1186-1189 (1998).
97. Nery JR, Weppler D, Rodriguez M et al. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65(12), 1615-1621 (1998).
98. Honkoop P, de Man RA, Zondervan PE et al. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17(2), 103-106 (1997).
99. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28(2), 585-589 (1998).
100. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123(3), 719-727 (2002).
101. Mutimer D, Pillay D, Dragon E et al. High pretreatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation. J. Hepatol. 30(4), 715-721 (1999).
102. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 29(5), 1581-1586 (1999).
103. Malkan G, Cattral MS, Humar A et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 69(7), 1403-1407 (2000).
104. Fontana RJ, Keeffe EB, Carey W et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 8(5 , 433-439 (2002).
105. Ben-Ari Z, Mor E, Shapira Z et al. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl. 7(2), 113-117 (2001).
106. Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122(2), 264-273 (2002).
107. Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping s gene. Virology 299(1), 88-99 (2002).
108. Delaney WE IV, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77(21), 11833-11841 (2003).
109. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38(6), 1419-1427 (2003).
110. Thomas DL, Cannon RO, Shapiro CN et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among nonintravenous drug-using patients attending clinics for sexually transmitted diseases. J. Infect. Dis. 169(5), 990-995 (1994).
111. Rector WG Jr, Govindarajan S, Horsburgh CR Jr et al. Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am. J. Gastroenterol. 83(3), 262-266 (1988).
112. Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. J. Acquir. Immune Defic. Syndr. 24(3), 211-217 (2000).
113. Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32(5), 1117-1124 (2000).
114. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30(4), 1054-1058 (1999).
115. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 360(9349), 1921-1926 (2002).
116. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32(3), 492-497 (2001).
117. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J. Am. Med. Assoc. 283(1), 74-80 (2000).
118. Di Martino V, Thevenot T, Colin JF et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123(6), 1812-1822 (2002).
119. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 125(9), 705-712 (1996).
120. Dore GJ, Cooper DA, Barrett C et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J. Infect. Dis. 180(3), 607-613 (1999).
121. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30(5), 1302-1306 (1999).
122. Hoff J, Bani-Sadr F, Gassin M et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of antihuman immunodeficiency virus regimens. Clin. Infect. Dis. 32(6), 963-969 (2001).
123. Thibault V, Benhamou Y, Seguret C et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J. Clin. Microbiol. 37(9), 3013-3016 (1999).
124. Bruno R, Sacchi P, Malfitano A et al. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 121(4), 1027-1028 (2001).
125. Bonacini M, Kurz A, Locarnini S et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 122(1), 244-245 (2002).
126. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV-infected patients. J. Hepatol. 36(Suppl. 1), 138 (2001).
127. Benhamou Y, Thibault V, Vig P et al. Long-term treatment with adefovir dipivoxil for 3 years in patients with lamivudine-resistant HBV and HIV coinfection results in significant and sustained clinical response. Hepatology 38(Suppl. 1), 714A (2003).
128. Nelson M, Portsmouth S, Stebbing J et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals. AIDS 17(1), F7-F10 (2003).
129. Liu CJ, Chen PJ, Lai MY et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 37(3), 568-576 (2003).
130. Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of interferon-α2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol. 35, 406-411 (2001).
131. Mutimer D, Naoumov N, Honkoop P et al. Combination α-interferon and lamivudine therapy for α -interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol. 28, 923-929 (1998).
132. Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J. Hepatol. 38(6), 818-826 (2003).
133. Santantonio T, Niro GA, Sinisi E et al. Lamivudine/interferon combination therapy in and-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. 36(6), 799-804 (2002).
134. Tatulli I, Francavilla R, Rizzo GL et al. Lamivudine and α-interferon in combination long-term for precore mutant chronic hepatitis B. J. Hepatol. 35(6), 805-810 (2001).
135. Mommeja-Marin H, Mondou E, Blum MR et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37(6), 1309-1319 (2003).
136. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. 2(2), 87-106 (2004).
137. Cooksley WGE, Piratvisuth R, Lee SD et al. Peginterferon-α2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 10(4), 298-305 (2003).
138. Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin. Investig. Drugs. 12(4), 683-688 (2003).
139. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin. Infect. Dis. 37(7), 944-950 (2003).
140. Hodge RA. Telbivudine/Torcitabine Idenix/Novartis. Curr. Opin. Investig. Drugs. 5(2), 232-241 (2004).
141. Han SH, Leung NWY, Teo EK et al. Results of a 1-year international Phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B. J. Hepatol. 40(4), A42 (2004).
142. Lok ASF, McMahon J. Chronic hepatitis B: update of recommendations. Hepatology 39(3), 857-861 (2004).